Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%

Pallavi Madhiraju- September 15, 2024 0

Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim ... Read More

EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment

Pallavi Madhiraju- August 28, 2024 0

Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More

Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer

Pallavi Madhiraju- August 22, 2024 0

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More

Kineta Inc. resumes VISTA-101 trial enrollment for KVA12123 in advanced solid tumors

Pallavi Madhiraju- August 20, 2024 0

Kineta Inc. has announced the resumption of patient enrollment in its VISTA-101 Phase 1/2 clinical trial, which is evaluating the efficacy of KVA12123 in treating ... Read More

Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment

Pallavi Madhiraju- July 14, 2024 0

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More

Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer

Pallavi Madhiraju- February 18, 2024 0

In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More

Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial

Pallavi Madhiraju- January 29, 2024 0

Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

Pallavi Madhiraju- January 28, 2024 0

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

FDA approves Merck’s KEYTRUDA for advanced cervical cancer treatment

Pallavi Madhiraju- January 14, 2024 0

Merck, known as MSD outside of the United States and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its ... Read More

Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma

Pallavi Madhiraju- December 15, 2023 0

Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative ... Read More